China Universal Asset Management Company’s Corvus Pharmaceuticals CRVS Stock Holding History

China Universal Asset Management Company’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$319K	Sell	21,383 -5,772	-21%	-$80.1K	0.02%	309
2026 Q1	$397K	Buy	27,155 +8,986	+49%	+$143K	0.03%	280
2025 Q4	$140K	Buy	18,169 +5,108	+39%	+$40.3K	0.01%	381
2025 Q3	$96.3K	Sell	13,061 -2,427	-16%	-$12.4K	0.01%	389
2025 Q2	$62K	Buy	15,488 +2,599	+20%	+$9.46K	0.01%	405
2025 Q1	$41K	Sell	12,889 -736	-5%	-$3.47K	﹤0.01%	429
2024 Q4	$72.9K	Buy	+13,625	New	+$102K	0.01%	422
2022 Q4	–	Sell	-436	Closed	–	–	413
2022 Q3	$0	Buy	+436	New	+$416	﹤0.01%	444

Other funds holding CRVS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

SAM

SEB Asset Management Stockholm $26.6B AUM

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

China Universal Asset Management Company's CRVS Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Corvus Pharmaceuticals (CRVS) stake by 21% in Q2 2026, selling an estimated $80.1K and leaving 21,383 shares worth $319K. The position accounts for 0.02% of the portfolio, ranked #309.

China Universal Asset Management Company first reported a position in CRVS in Q3 2022 and has held it in 8 quarters since. The position peaked at $397K in Q1 2026. 86 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

China Universal Asset Management Company held 21,383 shares of Corvus Pharmaceuticals worth $319K as of Q2 2026.
China Universal Asset Management Company sold 5,772 Corvus Pharmaceuticals shares in Q2 2026, an estimated $80.1K.
Corvus Pharmaceuticals made up 0.02% of China Universal Asset Management Company's portfolio in Q2 2026, its #309 holding.
China Universal Asset Management Company first reported a position in Corvus Pharmaceuticals in Q3 2022 and has held it in 8 quarters since.
China Universal Asset Management Company's Corvus Pharmaceuticals position peaked at $397K in Q1 2026.
86 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.